Cardiac surgery: UK PCI procedures to rise 5.4%

Published By Datamonitor

D-day for diabetes drugmakers

Spanish researchers could be on the brink of curing type 1 diabetes. While this breakthrough is undoubtedly good news for patients, drugmakers could lose out, as the market vanishes before their eyes. But this could not be their biggest threat: anti-obesity drugs could stop people developing diabetes at all - is this the end for diabetes drugs?

Published By Datamonitor

Diabetes: mice cured, now trying people

Although much further research is required, it could be viable to develop a genetic therapy for humans based on this discovery. While this could pose a threat to pharma companies in the $11.5 billion diabetes market, these firms are also in a strong position to exploit the new discoveries.

Published By Datamonitor

Spanish hip implants: ceramic-on-ceramic to more than double

Published By Datamonitor

Coping with new realities in asthma

Asthma is a chronic, long-term and prevalent disease - and thus, a major cost center for healthcare systems. This makes it a prime target for government efforts to reduce spending on drug reimbursement, potentially spelling trouble for pharma companies in the market. But how much impact will these changes have, and how can companies best cope with them?<BR />

Published By Datamonitor

CryoCor: competing in cardiac cryoablation

Published By Datamonitor

Epilepsy: 6.3 million cases in 2008

Published By Datamonitor

Anticonvulsants: potential sales growth in off-label expansion

Published By Datamonitor

Healthcare R&D: portfolio management governed by order of entry and strategic fit

Published By Datamonitor

Migraines prevention or cure, but please do something!

Published By Datamonitor